GLP-1 side effects: what fitness creators get right and wrong

What did @joshbricefitness actually say?

Josh Brice argues that GLP-1 drugs like semaglutide and tirzepatide were created to manage blood sugar and insulin, not to suppress appetite, and that people misusing them as appetite-suppression tools are eating under 1,000 calories and wrecking their health as a result. His core thesis: "fat loss doesn't happen by eating less and moving more, it occurs by having a healthy... metabolism and managing your insulin." He positions these drugs as insulin-management tools that have been hijacked by a calorie-restriction mindset. The 121,000-plus people who watched this got a confident, partially correct, but meaningfully flawed take on how these drugs actually work and why they were developed.

Does the science back this up?

Partially, and the parts that are wrong matter. GLP-1 receptor agonists were indeed first developed in a diabetes context, where glycemic control was the primary endpoint. That part checks out. But the claim that appetite suppression was incidental or unintended is not accurate. Appetite regulation through the hypothalamus and GI tract was identified as a mechanism of interest early in GLP-1 research, and modern agents like semaglutide were explicitly developed with weight loss as a target outcome, not a side effect. The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) enrolled adults with obesity but without diabetes specifically to test weight loss, which tells you all you need to know about intent. The insulin-fat storage framing has some basis in physiology but is heavily oversimplified in ways that can mislead people about what actually drives fat gain.

What did they get right, and where did they go wrong?

Credit where it is due: the concern about severe caloric restriction on GLP-1 therapy is legitimate and underreported. Hair loss, brittle nails, and poor skin on these medications are often signs of protein and micronutrient deficiency, not drug toxicity. Research supports the importance of adequate protein during GLP-1-assisted weight loss to preserve lean mass (Wilding et al., 2021; Rubino et al., 2022, Diabetes Care). Recommending high protein intake is solid advice.

But calling insulin "the fat storing hormone" as if it alone controls body weight is a reductive framing that has been popularized in fitness circles for years without strong support. Body fat regulation involves energy balance, leptin signaling, cortisol, sleep, genetics, and dozens of other factors. The claim that "if we can manage our insulin we can simply manage fat loss" is not what the evidence shows. Multiple meta-analyses, including Hall and Guo (2017, Cell Metabolism), found no significant fat loss advantage from low-insulin dietary approaches when calories are matched. Insulin is part of the picture, not the whole canvas.

The suggestion that GLP-1 drugs were "created to manage your blood sugar levels" and not for appetite suppression is also just historically inaccurate. Tirzepatide's dual GIP/GLP-1 mechanism and the entire SURMOUNT trial program were appetite and weight-focused by design.

What should you actually know?

GLP-1 receptor agonists work through multiple pathways at once: slowing gastric emptying, signaling satiety in the brain, and improving insulin sensitivity. These are not separate effects where one is "the real reason" and others are misuse. Appetite suppression is a core, intended mechanism, not a bug that patients are exploiting.

That said, the concern about people using extreme caloric restriction on top of GLP-1 therapy is real and worth taking seriously. Eating under 1,000 calories daily creates genuine risks of muscle loss, nutrient deficiency, and metabolic adaptation. A 2023 position statement from the Obesity Medicine Association recommends maintaining adequate protein (at minimum 1.2g per kg of body weight) during GLP-1-assisted weight loss to protect lean tissue.

• GLP-1 drugs reduce appetite through direct hypothalamic signaling, not as a side effect
• Severe caloric restriction on these drugs increases risk of sarcopenia and nutrient deficiency
• Insulin resistance is a real driver of metabolic dysfunction, but it is not the only factor in fat storage
• High protein intake during GLP-1 therapy is evidence-supported advice
• The "insulin is the fat hormone" framing has been tested and largely does not hold up when calories are controlled